For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.
BRISBANE, Calif., April 15, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc.
RICHMOND, Calif., April 8, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc.
RICHMOND, Calif., April 4, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc.
RICHMOND, Calif., April 3, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc.
Market players are more skeptical of the quick moves on U.S.-China trade news.
Sometimes dull action like this can be good for trading.
The stock surges on 'encouraging' results from a genome-therapy trial for the treatment of a severe type of hemophilia.
- Eight patients treated with SB-525 gene therapy showed dose-dependent increases in FVIII activity, with the two patients treated with the 3e13 vg/kg dose reaching normal FVIII levels
- Balanced in-house and contract manufacturing strategy to provide clinical and commercial supply for Sangamo's growing pipeline of AAV-based genomic therapies
‒ Conference call and webcast scheduled for 8:00 a.m. Eastern Time today
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, and Pfizer, Inc.
BRISBANE, Calif., April 1, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc.
- Sangamo's gene regulation platform technology fuses zinc finger proteins with transcription factors (ZFP-TFs)
Investors in Sangamo Therapeutics Inc saw new options begin trading this week, for the November 15th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
BRISBANE, Calif., March 12, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc.
-- Data published in Nature Communications show new architectures increase targeting capabilities by 64-fold
BRISBANE, Calif., March 6, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc.
Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time
BRISBANE, Calif., Feb.
Company plans to initiate the Phase 1/2 clinical trial for ST-920 in 2019
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sangamo Therapeutics Inc , where a total of 21,510 contracts have traded so far, representing approximately 2.2 million underlying shares. That amounts to about 128.3% of SGMO's average daily trading volume over the past month of 1.7 million shares.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
-- Administration of SB-318 was generally well tolerated in all 3 subjects across 2 dosing cohorts, up to a dose of 5e13 vg/kg (2 patients)
- Liver biopsy analysis detected targeted integration of IDS transgene, providing preliminary molecular evidence of in vivo genome editing in humans
Let's take a look at the charts and indicators.
From small-cap genetics and biotech firms to large-cap drug distributors and pharmacies, eight experts select their top picks in the space for this year.
Jim Cramer talks about how this market is taking its cues from the positives, and shrugging off the negatives.
